Effects of Dengzhanxixin Capsule on Platelet Function in Individuals at High Risk for Cardiovascular Disease (FUTURE)
Diabetes, Hypertension, Hypercholesterolemia
About this trial
This is an interventional prevention trial for Diabetes focused on measuring dengzhanxixin capsule; platelet function; primary prevention
Eligibility Criteria
Inclusion Criteria:
The following three conditions must be met at the same time:
- Age > 40 years, < 70 years
Meet any of the following conditions:
i) Diabetes
ii) LDL-C ≥ 4.9 mmol/L or TC ≥ 7.2 mmol/L
iii) Hypertension; 1.8 mmol/L ≤ LDL-C < 2.6 mmol/L or 3.1 mmol/L ≤ TC < 4.1 mmol/L; 3 risk factors (including smoking, HDL-C < 1.0 mmol/L, ≥ 45 years for male or ≥ 55 years for female)
iv) Hypertension; 2.6mmol/L ≤ LDL-C < 4.9mmol/L or 4.1mmol/L ≤ TC < 7.2mmol/L; with 2 or more risk factors (same risk factors as above)
- Sign the informed consent
Exclusion Criteria:
Those who meet any of the following conditions are not eligible:
- Diagnosed ASCVD, such as coronary heart disease, stroke and peripheral vascular disease
- Past history of heart failure
- History of symptomatic non-traumatic intracerebral hemorrhage at any time
- History of gastrointestinal bleeding within the past 3 months or history of major surgery within 30 days
- Need to use anticoagulation, antiplatelet or frequent use of non-steroidal anti-inflammatory drugs
- Have used Dengzhanxixin or preparations containing Dengzhanxixin in the past 1 month
- Have clear adverse reactions to Dengzhanxixin in the past
- Active liver disease, or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels > 2 times the upper limit of normal (ULN)
- Chronic kidney disease, or estimated glomerular filtration rate (eGFR) <60ml/(min×1.73m2)
- Pregnant or planning to become pregnant, or breastfeeding
- Malignant tumors, or other serious diseases with an expected survival period of less than 1 year
- Mental disorders or communication disorders, cognitive dysfunction, or other serious diseases that may affect participation in the study
- Have participated in or are participating in other clinical trials in the past 1 month
- Known poor adherence to study follow-up or study medication
- Acute stage of disease: acute fever, acute pancreatitis, etc.
In addition, subjects will be excluded from the randomization clinic if they have any of the following situations:
- Failure to complete the lead-in treatment
- The occurrence of placebo-related adverse reactions
Sites / Locations
- Fuwai Hospital, Chinese Academy of Medical Sciences, ShenzhenRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Placebo Comparator
Intervention group A
Intervention group B
Control group
Dengzhanxixin Capsules plus Placebo Capsules
Dengzhanxixin Capsules plus Placebo Capsules
Placebo Capsules